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AutosomAl recessive AtAxiAs
20 types, and counting
Emília Katiane Embiruçu1 , Marcília Lima Martyn1, David Schlesinger2, Fernando Kok3
Abstract – More than 140 years after the first description of Friedreich ataxia, autosomal recessive ataxias 
have become one of the more complex fields in Neurogenetics. Currently this group of diseases contains 
more than 20 clinical entities and an even larger number of associated genes. Some disorders are very rare, 
restricted to isolated populations, and others are found worldwide. An expressive number of recessive ataxias 
are treatable, and responsibility for an accurate diagnosis is high. The purpose of this review is to update the 
practitioner on clinical and pathophysiological aspects of these disorders and to present an algorithm to 
guide the diagnosis.
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Ataxias autossômicas recessivas: 20 tipos e muito mais
resumo – Mais de 140 anos após a primeira descrição da ataxia de Friedreich, as ataxias autossômicas 
recessivas se transformaram em um dos mais complexos campos da Neurogenética. Atualmente, este grupo 
de doenças é composto por mais de 20 entidades clínicas e possui um número ainda maior de genes associados. 
Algumas doenças são muito raras, tendo sido observadas apenas em populações isoladas, enquanto que outras 
são encontradas no mundo todo. Um número expressivo de ataxias é tratável, e a responsabilidade em se 
fazer um diagnóstico correto é alta. A finalidade desta revisão é a de atualizar o neurologista a respeito dos 
principais aspectos clínicos e fisiopatológicos destas doenças e de apresentar um algoritmo para auxiliar a 
sua investigação e o seu diagnóstico. 
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More than 20 different clinical types of autosomal re-
cessive ataxias (ARA) are currently recognized. They are 
clinically characterized by balance abnormalities, incoor-
dination, kinetic and postural tremor, and dysarthria1. Typ-
ically, symptoms start before 25 years of age, and cerebel-
lum, brainstem, and spinocerebellar tracts are involved2. 
Peripheral neuropathy, ophthalmological abnormalities, 
and non-neurological signs and symptoms might also be 
present1. Friedreich ataxia, the most common ARA, was 
first described in 1863 and is seen worldwide1,2. In the last 
few years, several other conditions have also been recog-
nized and their loci and genes identified. 
Pathophysiology is quite variable and the defective 
gene product might be involved with: (A) Cerebellar and/
or brain stem development; (B) Mitochondrial energy gen-
eration; (C) Intermediate metabolism; (D) DNA repair; and 
(E) Cerebellar integrity maintenance. Several classifica-
tions have been proposed so far, using clinical, neuroim-
aging, genetic and pathophysiologic data2. In this review, 
a pathophysiological classification is used (Table 1). 
We should be particularly aware of treatable forms of 
ARA, which includes Refsum disease, ataxia with vitamin 
E deficiency, coenzyme Q10 deficiency, cerebrotendinous 
xanthomatosis, and abetalipoproteinemia. 
Arq Neuropsiquiatr 2009;67(4)
1144
Autosomal recessive ataxias
Embiruçu et al.
Table 1. Classification and molecular aspects of the autosomal recessive ataxias
Gene (Locus) Protein Protein function
Congenital
Cayman ataxia ATCAY (19p13.3) Caytaxin Synapse between granulates 
and Purkinje cells (?)
Joubert syndrome AHI1 (16q23.3) Jouberin Cerebellar estruturation; cilia 
estruturation and functions 
NPHP1 (2q13) Nefrocistin-1
CEP290 (12q21.34) Nefrocistin-6
TMEM67 (8q21.1-q22.1) Meckelin
RPGRIP1L (16q12.2) Protein phantom
Cerebellar hypoplasia associated VLDL receptor VLDLR (9p24.2-3) VLDL Receptor Signalling neuroblast migartion
Mitochondrial
Friedreich ataxia FRDA (9q13) Frataxin Mitochondrial iron metabollism
Coenzyme Q10 deficiency with  
cerebellar ataxia
PDSS1 (10p12.1) and 
PDSS2 (6q21)
Prenyldiphosphate 
synthase subunit 1 e 2
Coenzyme Q10 biosynthesis
COQ2 (4q21-q22) OH-benzoate polyiprenyl 
transferase
Coenzyme Q10 biosynthesis
ADCK3 (CABC1) (1q42.2) ADCK3 (Mitochondrial protein) Coenzyme Q10 biosynthesis
Ataxia with mutation in polymerase gamma POLG (15q22-26) DNA polymerase g Mitochondrial DNA maintenance
Infantile onset spinocerebellar ataxia C10orf2 (10q24) Twinkle Mitochondrial DNA repair 
and maintenance
Metabolic
Ataxia with vitamin E deficiency a-TTP (8q13.1-13.3) a-tocopherol transfer protein a-tocopherol 
incorporation in VLDL
Abetalipoproteinemia MTP (4q22-24) Microsomal tryigliceride 
transfer protein
Lipoprotein metabolism
Refsum disease PHYH (10pter-11.2) Phytanoyl-CoA hydroxylase Fatty acid a-oxidation 
PEX7 (6q21-22.2) Peroxisomal biogenesis factor-7 Peroxisomal protein importation
Cerebrotendinous xanthomatosis CYP27 (2q33-ter) Sterol 27-hydroxylase Bile acid synthesis
DNA repair defects
Ataxia telangiectasia ATM (11q22.3) Ataxia telangiectasia mutated DNA double-strand break repair
Ataxia-telangiectasia- like disorder MRE11A (11q21) Meiotic recombination 11 DNA double strand break repair
Ataxia with oculomotor apraxia type 1 APTX (9p13) Aprataxin DNA single strand break repair
Ataxia with oculomotor apraxia type 2 SETX (9q34) Senataxin DNA and RNA repair
Spinocerebellar ataxia with axonal neuropathy TDP1 (14q31-32) Tyrosyl DNA
phosphodiesterase I
DNA repair
Degenerative
Spastic ataxia of Charlevoix Saguenay SACS (13q11) Sacsin Chaperone-mediated 
protein foling
 Marinesco-Sjögren syndrome SIL1 (5q31) BiP associated protein Stabilization and folding of newly 
synthesized polypeptides
Legend: (?), possibly.
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AtAxiA cAused by cerebellAr And/or  
brAinstem mAlformAtion
In this group, neuroimaging studies are able to identi-
fy cerebellar and/or brainstem malformation and clinical-
ly it is characterized by non progressive cerebellar atax-
ia. Three conditions are discussed in this section: Cayman 
ataxia, Joubert syndrome and Cerebellar hypoplasia asso-
ciated to VLDL receptor.
Cayman ataxia
Cayman ataxia (CA) is a condition characterized by 
variable developmental delay, early onset hypotonia and 
non-progressive axial cerebellar ataxia, associated to ny-
stagmus, intention tremor, and dysarthria3. MRI presents 
with cerebellar hypoplasia3. The CA has only been found 
in Grand Cayman Island, where heterozygote frequen-
cy is supposed to be of 18%3. CA is caused by mutation 
at ATCAY, which codes for caytaxin, a protein involved 
with glutamate synthesis and also with synaptogenesis 
of cerebellar granular neurons and Purkinje cells4. Inter-
estingly, ATCAY contains a CRAL-TRIO domain that binds 
small lipophillic molecules, similar to the alpha-tocoph-
erol transport protein that causes ataxia with vitamin E 
deficiency3.
Joubert syndrome
Joubert syndrome (JS) is a rare genetically heteroge-
neous inherited disorder with an estimated prevalence in 
the United States of 1 in 100,0005. JS is characterized by 
congenital ataxia, hypotonia, developmental delay, and 
at least one of the following features: neonatal respira-
tory disturbances and abnormal eye movements (nystag-
mus or oculomotor apraxia). In some cases, Leber congen-
ital amaurosis, pigmentary retinopathy, renal and hepatic 
abnormalities can also be found. A combination of mid-
line cerebellar vermis hypoplasia, deepened interpedun-
cular fossa, and thick, elongated superior cerebellar pe-
duncles gives the axial view of the midbrain the appear-
ance known as molar tooth sign (Fig 1), an obligate find-
ing for JS diagnosis5-7. 
Recently, Valente, Brancati and Dallapiccola6 proposed 
a clinical classification of JS in which the molar tooth sign 
was considered an obligatory criterion. They were able to 
recognize six subgroups of JS: (1) Pure Joubert syndrome; 
(2) JS with retinal abnormality; (3) JS with renal disorders; 
(4) CORS (cerebello-oculo-renal syndrome), or JS with ret-
inal abnormality and kidney involvement; (5) COACH (cer-
ebellar vermis hypoplasia/aplasia, oligophrenia, ataxia, 
ocular coloboma, and hepatic fibrosis) or JS with mental 
retardation, ocular coloboma and liver disorder; and (6) 
Oro-facio-digital syndrome type VI, or JS with orofacial 
abnormality and polydactylia. 
Seven loci and five genes have been identified so far 
(Table 2)6. It is believed that other loci and genes will be 
recognized in the future, as mutations in known genes ac-
count for only a small fraction of patients. There is no 
clear correlation between genetic and clinical in JS, none-
theless, AHI1 mutations are usually associated with pure 
JS and approximately 50% of individuals with cerebello-
oculo-renal syndrome have CEP290 mutations6,7. In large 
series, mutations in AHI1 are found in 10 to 15% of cases, 
and of CEP290 in 10%5. 
Cerebellar hypoplasia associated with VLDL receptor 
Cerebellar hypoplasia associated with very low densi-
ty lipoprotein (VLDL) receptor (CHVR) is clinically charac-
terized by severe developmental delay, hypotonia, global 
ataxia, flat feet, strabismus, and moderate to severe men-
tal retardation8,9. Epilepsy and short stature might occa-
sionally be seen8. MRI discloses a symmetric cerebellar 
hypoplasia, mostly of its inferior segment, with variable 
brainstem and corpus callosum hypoplasia, and plain cor-
tical gyrus8,9. This form of non-progressive cerebellar atax-
ia was first reported as disequilibrium syndrome among 
North-Americans Hutterites8. CHVR is caused by mutation 
in the gene that encodes VLDL receptor (VLDLR)9. This 
transmembrane protein is part of reelin signaling path-
way, which guides neuroblast migration in the develop-
ing cerebellum and cerebral cortex9.
Fig 1. Molar tooth sign (arrow) in axial RMI images, for a patient with 
Joubert syndrome.
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AtAxiAs cAused by deficiency of  
mitochondriAl energy generAtion
Ataxias caused by deficiency of mitochondrial energy 
generation includes Friedreich ataxia, Ataxia with CoQ10 
deficiency, Mitochondrial recessive ataxic syndrome 
(MIRAS) and Infantile-onset spinal cerebellar ataxia (IOSCA).
Friedreich ataxia
Friedreich ataxia (FA) is the most common recessive 
ataxia worldwide, with an estimated prevalence in Cau-
casian population of 1:30,000 to 1:50,00010 and a carrier 
frequency of 1:851. Its onset is usually in the second de-
cade of life, but can vary from 2 to 25 years of age. Clini-
cal manifestations are characterized by a combination of 
sensory and cerebellar symptoms, and gait instability is 
usually the first recognized abnormality. Relentlessly pro-
gressive ataxia is characteristic, and after 10 to 15 years of 
onset, patients are usually wheelchair bound. Dysarthria 
is also an early and incapacitating symptom, leading to 
an almost incomprehensible speech. Vibratory and posi-
tional sense is affected, and Romberg sign is usually posi-
tive. Deep tendon reflexes are absent, but extensor plan-
tar reflex (Babinski sign) is usually present. Abnormal eye 
movements and defective fixation are also observed. Cog-
nitive function is preserved, but communication abilities 
can be affected. Systemic abnormalities as hypertrophic 
cardiomiopathy, cardiac conduction defects and diabetes 
can occur. As disease progresses, pes cavus and scoliosis 
are almost always present. Although there are significant 
variations in the onset and rate of disease progression, the 
mean age of death has been reported to be approximately 
38 years, with a range as wide as 5 to 70 years. Death usu-
ally is secondary to progressive cardiomyopathy10.
Brain MRI in FA is normal; using the multigradient echo 
sequence it is sometimes possible to detect iron depos-
its in dentate nuclei of cerebellum. Spinal cord MRI can 
disclose mild atrophy of its cervical segment, which is ex-
plained by the large loss of primary sensory neurons in 
the dorsal root ganglia, early in the course of the disease. 
Nerve conduction studies characteristically show axonal 
sensory neuropathy10. Atypical forms of FA, as late on-
set or with maintained reflexes, have been proposed, but 
it is now clear that they are also caused by mutations in 
the same gene.
FA is caused by mutations in the FRDA gene, which en-
codes frataxin, a protein involved in mitochondrial iron 
regulation. Loss of mitochondrial iron-sulfur centers, im-
pairment of mitochondrial respiratory chain, increased 
mitochondrial iron and increased oxidative damage are 
observed when frataxin is deficient. Almost all patients 
are homozygotes for a GAA expansion which occurs in 
intron 1 of FRDA gene. Normal individuals have up to 40 
GAA repeats, and in patients this number can vary from 70 
or 90 to over 1,700 repeats. Presence of biallelic expansion 
confirms diagnosis, independent of clinical phenotype10,11. 
Close to 2% of patients are compound heterozygotes, 
with a combination of a GAA expansion in one allele and 
a point mutation in the other1. 
Coenzyme Q10 (CoQ10), and its synthetic analog ide-
benone, vitamin E and, more recently the iron chelator 
deferiprone have been used for treating FA, with some 
promising but still very preliminary results12,13. Deferiprone, 
an atypical iron chelator, may decrease accumulation of 
toxic iron in the mitochondria in patients, but the recom-
mended dose and the efficiency of this treatment have 
not yet been determined12.
Ataxia with coenzyme Q10 deficiency
Primary deficiency of coenzyme Q10 (CoQ10) is a ge-
netically heterogeneous disorder, with a highly variable 
clinical spectrum, which includes multi-systemic man-
ifestations as well as CNS compromise14-16. Five clinical 
subtypes have been recognized: (1) Encephalomyophat-
ic, with mitochondrial myopathy, recurrent myoglobinu-
ria and CNS symptoms and signs; (2) Early infantile multi-
systemic, with severe visceral and brain manifestations; (3) 
Leigh syndrome; (4) Pure myopathic; (5) Ataxic14,15,17. 
The ataxic subtype is the most common presentation 
of CoQ10 deficiency14,15. It is characterized by progressive 
ataxia, cerebellar atrophy and reduced muscle CoQ1014,15. 
Early symptoms might include developmental delay, hy-
potonia and frequent falls. Global, progressive ataxia, and 
dysarthria start before the adolescence17. Epileptic sei-
zures, proximal or distal muscle weakness, dysphagia, oph-
thalmoparesis, nystagmus, peripheral axonal neuropathy, 
pyramidal signs and scoliosis might also be present14,15,17. 
Mental retardation or cognitive decline is also sometimes 
seen14,17. The adult onset form of ataxia and CoQ10 de-
ficiency is usually associated with hypergonadotrophic 
hypogonadism14. 
CoQ10 (also known as ubiquinone) is a lipophylic com-
Table 2. Joubert syndrome identified loci, genes and their 
products.
Locus Location Gene Protein
JBTS1 9q34.3 Not known Not known
JBTS2 11p12-q13.3 Not known Not known
JBTS3 6q23.3 AHI1 Jouberin
JBTS4 2q13 NPHP1 Nephrocystin-1
JBTS5 12q21.34 CEP290 
(NPHP6)
Nephrocystin-6
JBTS6 8q21.1-q22.1 TMEM67 Meckelin 
JBTS7 16q12.2 RPGRIP1L Protein phantom
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pound which is involved in electron transport from com-
plex I and II to complex III of mitochondrial respiratory 
chain14-17. CoQ10 deficiency impairs proton transfer across 
the internal mitochondrial membrane and consequently 
to a reduction in ATP production14,16. 
The main source of CoQ10 is endogenous synthesis, 
which involves a still-uncharacterized complex pathway. 
Four genes are known to be involved in CoQ10 biosynthe-
sis: PDSS1 e PDSS2 (subunits 1 and 2 of prenyldiphosphate 
synthase), COQ2 (OH-benzoate polypreniltransferase) and 
ADCK3, which acts as a chaperone14,16. 
Diagnosis is based on reduced amount of CoQ10 in 
muscle, as plasma CoQ10 levels are usually normal14,15,17. 
Muscle histopathology is essentially normal and brain MRI 
discloses global cerebellar atrophy14,17. Treatment with oral 
CoQ10 should be adjusted according to clinical results, 
with doses varying from 300 to 3000 mg/day14,17. Treat-
ment outcome is quite variable: in some patients disease 
stabilized while in others it progressed relentlessly. It is 
probable that treatment response is dependable of under-
lying biochemical defect as well as stage of disease14,15,17. 
Ataxia with mutation in polymerase gamma 
Polymerase gamma (POLG) is a nuclear encoded gene, 
whose product is responsible for maintaining the integrity 
of mitochondrial DNA18. Mutations in POLG are associated 
with a variety of clinical phenotypes, which includes Alp-
ers disease, parkinsonism, and external progressive oph-
thalmoplegia18. Two similar forms of autosomal recessive 
ataxias are associated with mutations in POLG: Mithoc-
ondrial Recessive Ataxic Syndrome (MIRAS) and Senso-
ry Ataxia, Neuropathy, Dysarthria, and Ophthalmoplegia 
(SANDO)18,19. 
MIRAS is the most frequent recessive ataxia in 
Finland1,20. Clinical manifestations, which start between 5 
to 40 years of age, are characterized by cerebellar atax-
ia, nystagmus, dysarthria, ophthalmoplegia, tremor, cog-
nitive decline, and myoclonus. Loss of vibratory and po-
sition perception is commonly seen19,20. Epilepsy is a fre-
quent manifestation in MIRAS, but not in SANDO, with 
both partial and generalized seizures, sometimes becom-
ing refractory to antiepileptic drugs and evolving to sta-
tus epilepticus18-20. Brain MRI discloses cerebellar atrophy 
and T2 weighed hypersignal on thalamus, and dentate and 
inferior olivary nuclei19,20. Nerve conduction studies also 
demonstrate axonal sensory neuropathy19,20. Elevated pro-
tein might be detected in CSF19,20. Muscle biopsy is not di-
agnostic, but Southern blotting analysis might detect mul-
tiple deletions in muscle mithocondrial DNA20. Diagnosis 
is based on sequencing of the POLG gene, with two muta-
tions (p.A467T and p.W748S) beeing responsible for most 
cases of this disorder in Caucasians19,20. There is no clear 
genotype-phenotype in this condition. 
Infantile-onset spinocerebellar ataxia 
Infantile-onset spinocerebellar ataxia (IOSCA) is cur-
rently identified only in Finland and is characterized by 
acute or subacute cerebellar signs triggered by unspecif-
ic infection around the age of 1 year21,22. Their clinical fea-
tures are similar to MIRAS. Hypotonia, athetosis of hands 
and face, and ataxia with absent reflexes are the ear-
ly symptoms this disease. Later at pre-school age, oph-
thalmoplegia and neurosensorial deafness might be seen. 
Tactile, proprioceptive, and vibratory impairment, with-
out pain or temperature compromise are detected after 
the first decade. Teenagers are usually wheelchair bound 
with severe distal muscular atrophy, pes cavus, mild to 
moderate cognitive impairment and optic atrophy with-
out significant visual impairment. Refractory epilepsy and 
status epilepticus might contribute to rapid neurological 
deterioration and death. Further recognized abnormali-
ties are autonomic dysfunction and, in females, primary 
hypogonadism21,22. 
There is no biochemical marker for IOSCA. Nerve con-
duction studies and nerve biopsy demonstrate a severe, 
mostly sensory, axonal neuropathy. Sensory ganglia are 
more severely affected than motoneurons21,23. Neuroim-
aging studies at early stages of disease demonstrate re-
duced size of cerebellar hemispheres which progress to a 
more widespread olivopontocerebellar atrophy23. Muscle 
biopsy is non-diagnostic but mitochondrial DNA deple-
tion might be seen in this tissue. Pathological studies dis-
close spinal cord atrophy (more intense on the posterior 
funiculli), cerebellum and brainstem; there is also marked 
loss of myelinated fibers on peripheral nerve21.
IOSCA is caused by mutation in C10ORF2 gene, which 
codes for twinkle, a specific mitochondrial DNA helicase, 
and one of its smaller isoform, twinky. Twinkle is impor-
tant for maintenance and replication of mitochondrial 
DNA, and twinky function is currently unknown. The same 
founder mutation (p.Y508C) was detected in most Finn-
ish patients with classical IOSCA. Mutations in C10ORF2 
might also be associated to different phenotypes, such as 
Alpers disease (early onset encephalopathy with untreat-
able epilepsy, mtDNA depletion and liver failure) and au-
tosomal dominant progressive external ophthalmoplegia22. 
metAbolic AtAxiAs
Metabolic ataxias are treatable disorders, and it is par-
ticularly important to make an early and accurate diagno-
sis in this group of ARA. Ataxia with vitamin E deficiency, 
abetalipoproteinemia, hipobetalipoproteinemia, Refsum 
disease and cerebrotendinous xanthomatosis will be dis-
cussed in this section. 
Ataxia with vitamin E deficiency 
Ataxia with vitamin E deficiency (AVED) is similar to 
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Friedreich ataxia (FA). Age of onset usually varied from 4 
to 20 years, with outliers ranging from 2 to 52 years24,25. 
Clinical manifestations are characterized by progressive 
trunk and limbs ataxia, dysarthria, disturbance of position-
al and vibratory lower limbs senses, Babinski sign and abol-
ished deep tendon reflexes. Scoliosis and pes cavus are 
commonly seen24-26, yet retinopathy is less frequent25,26. 
Dystonia (13%) and head titubation (28%) are more com-
monly seen in AVED than in FA24,26. Cardiomyopathy and 
an acute cardiac event might be associated with prema-
ture death among AVED cases25,26. 
AVED is caused by mutations in the a-tocopherol 
transfer protein gene (TTPA), which codes a protein re-
sponsible for transferring a-tocopherol from chilomicrons 
to VLDL26,27. TTPA disfunction causes very low level of cir-
culating a-tocopherol and tissue deficiency of this vita-
min27. Several different pathogenic mutations have been 
reported so far. Two mutations, associated with a severe 
phenotype, are particularly frequent in Europe, North Af-
rica and North America: c.744delA and c.486delT24,25. On 
the other hand, the mutation p.H101G was only detected 
in Japanese families and is associated with later onset and 
pigmentary retinopathy24. Age of onset, clinical manifesta-
tions and progression velocity are quite variable in AVED. 
It is usually stated that mutations causing profound TTPA 
protein depletion are responsible for a more severe phe-
notype and mutations leading to amino acid substitution 
are associated to a milder form of disease24-26. 
 Diagnosis in a symptomatic individual is established 
with the determination of a-tocopherol (vitamin E) serum 
level, which is always below 2.5 mg/ml (reference values: 
5-15 mg/ml)24,25. Brain MRI is usually normal, but mild cer-
ebellar atrophy might also be seen1,26. A pattern of axonal 
sensitive neuropathy is often observed at nerve conduc-
tion studies24.
AVED treatment consists of vitamin E oral adminis-
tration at a dose of 600 to 2,400 mg/day. Serum levels 
might be used as guidance for oral dose adjustment24-26. 
Differential diagnosis of a-tocopherol primary deficien-
cy includes intestinal fat mal-absorption and abetalipo-
proteinemia26. As a rule, vitamin E serum levels should be 
checked in all patients with FA clinical phenotype with-
out molecular confirmation for this condition.
Abetalipoproteinemia and hypobetalipoproteinemia
Abetalipoproteinemia (ABL), a multisystem disorder 
caused by a defect in lipoprotein metabolism, is charac-
terized by acanthocytosis, atypical pigmentary retinopa-
thy and spinocerebellar degeneration28,29. In the first year 
of life, main manifestations are chronic diarrhea and fail-
ure to thrive. Neurological features, present after the first 
decade of life, include absent deep tendon reflexes, su-
perficial and deep sensory abnormalities, weakness and 
global ataxia29. As disease progresses, atypical pigmentary 
retinopathy characterized by small, irregularly distributed 
white spots, and night and color blindness is detected29. 
Clinical manifestations of ABL are secondary to deficient 
absorption of the lipid-soluble vitamins A, D, E, and K1,28. 
Apolipoprotein B (ApoB) is the main protein of both 
VLDL and LDL, and their assembly is dependent on mi-
crosomal triglyceride transfer protein (MTP)28. Mutations 
in the gene coding for the large (88 kD) subunit of MTP is 
responsible for ABL and determine very low levels of LDL 
and VLDL cholesterol. Decreased levels of vitamins A, K, 
and E, anemia, very low sedimentation rate, increased pro-
thrombin time and elevated creatine kinase are also ob-
served. Deficient MTP can also lead to lipid infiltration of 
small bowel mucosa and hepatic steatosis28,29. Nerve con-
duction velocity usually discloses sensory axonal periph-
eral neuropathy1,29. 
ABL treatment is done with supplementation of vita-
min A (100 to 400 IU/Kg/day), vitamin E (2,400 to 14,400 
IU/day), and vitamin K (5 mg/day)29. It is also recom-
mended a low fat diet combined with essential fatty acid 
supplementation28,29. Coagulation tests are used to moni-
tor vitamin K and serum levels of vitamin A and E to check 
supplementation adequacy for these vitamins28,29. 
Hypobetalipoproteinemia (HBL) is similar to ABL. It is 
caused by mutations in APOB gene, which encodes apo-
lipoprotein B (ApoB)2. APOB heterozygotes have lower 
levels of ApoB, VLDL- and LDL-cholesterol, while MTP 
heterozygotes have normal levels of these substances2,29,30. 
Refsum disease 
Refsum disease (RD) is a peroxisomal disorder clini-
cally characterized by pigmentary retinopathy, cerebel-
lar ataxia, mixed motor-sensory neuropathy and elevat-
ed CSF protein31,32. Its onset usually occurs before 20 years 
of age, with night blindness secondary to retinopathy, fol-
lowed by progressive constriction of visual field and optic 
atrophy, cataracts, vitreous opacities and nystagmus32,33. 
Other common clinical manifestations are anosmia, co-
chlear deafness, ichthyosis, bone dysplasia and cardiac ab-
normalities31-33. Psychiatric disorders are uncommon31,33. If 
not adequately treated, RD can cause premature cardi-
ac death31,32. 
Elevation of serum phytanic acid (>200 mM/L; refer-
ence value <30 mM/L) is very suggestive, but not specif-
ic of RD31,33. Phytanic acid is a branched long chain fat-
ty acid present on dairy products and red meat33. It is a 
by-product of chlorophyll catabolism and is not endog-
enously synthesized31-33. Diagnostic confirmation can be 
made measuring the activity of phytanoyl-CoA hydroxi-
lase in fibroblasts or by molecular analysis of the respon-
sible gene31. 
RD is a genetically heterogeneous disorder. Most cas-
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es are caused by mutations in PHYH (encoding phytanoyl-
CoA hydroxylase), a peroxisomal matrix enzyme which 
catalyses -oxidation of branched chain fatty acids31-33. 
Deficiency in PEX7 (encoding peroxin-7), a protein in-
volved in peroxisomal import of some enzymes, in-
cluding phytanoyl-CoA hydroxylase, also results in this 
phenotype2,31. PEX7 mutations may also cause a severe 
peroxisomal biogenesis disorder known as rhizomelic 
chondrodysplasia punctata32. 
Treatment is based on phytanic acid dietary restric-
tion, combined, if necessary, with plasmapheresis. With 
reduction of phytanic acid serum levels, RD symptoms 
stabilize and there may be some improvement of atax-
ia and ichthyosis, albeit effects on pigmentary retinopa-
thy are uncertain32,33. 
Cerebrotendinous xanthomatosis
Cerebrotendinous xanthomatosis (CTX) is a rare bile 
acid synthesis disorder34. Its main clinical manifestations 
are juvenile cataracts, chronic diarrhea, and tendinous 
xanthomas34-36. In the neonatal period, a potentially le-
thal cholestatic syndrome has been reported34. After the 
second decade of life, progressive neurological deteriora-
tion may occur, characterized by cognitive decline, psychi-
atric manifestations, cerebellar ataxia, progressive spastic 
paraplegia, dysphagia, and less frequently, seizures and pe-
ripheral neuropathy34,36,37. Exceptionally, neurological man-
ifestations are restricted to the spinal cord35. There is a 
wide intra- and inter-familial clinical variability34,37. Coro-
nary heart disease without elevated cholesterol is an im-
portant cause of morbidity and mortality in adults34,35.
CTX is caused by mutations in CYP27A1 gene, which 
codes for sterol 27- hydroxylase, a protein expressed 
mostly in liver34,36. This enzyme is essential for bile ac-
ids synthesis, including chenodeoxycholic acid36. In the 
absence of sterol 27- hydroxylase, the substrate of this 
enzyme is converted to cholestanol by the action of 7 
a-hydroxylase34,36. Elevated serum cholestanol is the bio-
chemical hallmark of CTX35,37. Increased urinary excretion 
of bile alcohol glucuronides might also be present37. This 
disorder can be treated by oral administration of chen-
odeoxycholic acid, which inhibits 7 a-hydroxylase and 
consequentely cholestanol synthesis34-37. Liver transplant 
is another therapeutic alternative34. Cholestanol determi-
nation in asymptomatic siblings of CTX patients is recom-
mended to improve clinical outcome34,37. 
Brain MRI most distinctive abnormalities are detected 
at T2-weighed and FLAIR sequences, which demonstrate 
bilateral, heterogeneous and hyperintense sign in den-
tate nuclei and adjacent cerebellar white matter (Fig 2)35,36. 
Other less characteristic abnormalities which might be 
detected are brain stem, cerebellar and cerebral atrophy 
and diffuse hyperintense cerebral white matter lesions35,36. 
MR spectroscopy (MRS) of CTX patients discloses reduc-
tion of N-acetylaspartate and increase in lactate36. 
AtAxiAs With dnA rePAir defects
This group has as a common pathogeny a defect in 
double or single strand DNA repair; besides ataxia, extrin-
sic ocular movements are frequently affected. Ataxia-te-
langiectasia, ataxia telangiectasia-like, apraxia and oculo-
motor apraxia types 1, 2 and 3, and spinocerebellar ataxia 
with axonal neuropathy type 1 belong to this group. 
Ataxia-telangiectasia
Ataxia-telangiectasia (AT) has an estimated frequen-
cy in the USA of 1/40,000 individuals38 and it is predict-
ed that 0.5% of UK population carries one mutation in 
ATM gene, which is responsible for AT39. Progressive atax-
ia with onset before 3 years of age is the main clinical 
characteristic38,40. Telangiectasias (Fig 3), another hallmark 
of disease, are seen in at least 90% of affected individu-
als and their age onset ranges from 2 to 8 years; they are 
more easily seen in conjunctivas, ears, face and neck38,40,41. 
A large range of ophthalmological abnormities might also 
be detected, including: optokinetic nystamus (present in 
81% of cases), gaze induced nystamus (seen in 29%), hy-
pometric or delayed saccades (76%), delayed eye tracking 
(63%), strabismus (38%), and oculomotor apraxia (30%)41. 
Dysarthria, dysphagia, facial hypomimia, generalized hy-
potonia, peripheral neuropathy and movement disorder, 
as tremor or choreoathetosis, are seen after five years of 
age38,40,41. Cognitive level is usually normal, even though 
Fig 2. Cerebellar atrophy and hyperintense sign in dentate nuclei and 
adjacent cerebellar white matter on T2-weight RMI images (arrow), 
for a patient with cerebrotendinous xanthomatosis.
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severe dysarthria and incoordination might leave an im-
pression of mental retardation. Independent gait is lost 
by the end of first decade38,40. Immunodeficiency (main-
ly humoral) leading to chronic sinopulmonary infection 
and increased susceptibility to cancer are other impor-
tant features in AT. Risk of lymphoproliferative disorders 
are dramatically increased in AT38,40. Treating cancer in AT 
patients is particularly challenging, because of their in-
creased radiosensitivity and adverse side effects to che-
motherapy40. Female carriers of one mutated copy of the 
gene have 3–4 fold increased risk of breast cancer when 
compared to general population39. 
ATM gene encodes for a ATM serine/threonine kinase, 
a large protein with 3,056 amino acids which is part of the 
phosphatidyl-inositol-3-kinase (PI3-K) complex, responsi-
ble for DNA repair during the cell cycle, avoiding incorpo-
ration of deleterious mutations38,39. ATM gene is very large, 
containing 66 exons, and its sequencing with current tech-
nology is still cumbersome, but feasible38,39. Most patients 
are compound heterozygotes for ATM mutations and a 
large variety of sequence variants have been recognized, 
thus making interpretation of results difficult. Pathogen-
ic mutations are usually nonsense mutations (85%), and 
missense mutations are responsible for 10% of detected 
pathogenic changes38,39,40.
Some laboratory tests might help AT investigation: se-
rum alpha-fetoprotein is elevated in more than 95% of 
cases and low levels of IgA, IgE and reduced T lymphocyte 
count, with normal or elevated B lymphocytes are usually 
detected. Karyotype might show translocation between 
chromosomes 7 and 1438-41 and radiosensivity test might 
be used to demonstrate chromosomal breakage predis-
position. 
Brain MRI discloses, except in early stages of disease, 
cerebellar atrophy, which is initially more evident on the 
hemispheres and superior vermis and later becomes dif-
fuse38. CT-scan and plain radiography should be avoided 
because of increased X-ray sensitivity. 
Ataxia-telangiectasia like 
Ataxia-telangiectasia like (ATL) is a very rare clini-
cal condition which is characterized by slowly progres-
sive ataxia with onset between 1 and 7 years of age, as-
sociated to oculomotor apraxia and dysarthria42. No oc-
ular or facial telangiectasias are detected and cognition 
is preserved39,42,43. Reflexes might be initially brisk and be-
came reduced42. At advanced stages of disease, tongue 
and facial dyskinesia, choreoathetosis, and dystonia, sug-
gesting basal ganglia compromise, might be seen42,43. ATL 
is progressive up to the adolescence, when it stabilizes43. 
There is no increased risk for infections or neoplasias, as is 
seen in AT, but occasionally microcephaly is present39,42. 
Brain MRI detects cerebellar atrophy, and laboratory 
tests are non-informative43. Radiosensitivity test is usual-
ly present but in a lesser degree than in AT35,42-44.
ATL is caused by mutation in MRE11 gene, located in 
chromosome 11q21, near the ATM gene. Its product is 
part of the MRN complex, which recognizes DNA double 
strand breakage. Both missense and null mutations have 
been reported. Severity varies according to the type of 
molecular defect. Most of reported cases were original 
from Saudi Arabia 39,42-44.
Ataxia with oculomotor apraxia type 1 
Ataxia with oculomotor apraxia type 1 (AOA1) is a con-
dition characterized by involuntary movements (chorea 
and dystonia) and/or progressive global ataxia, with dys-
arthria associated with hands and head tremor. Onset can 
vary between 1 to 20 years of age and developmental de-
lay might be seen before clinical symptoms became appar-
ent. As disease progresses, movement disorder are atten-
uated and peripheral neuropathy signs, as distal atrophy, 
Fig 3. Ocular telangiectasia for a patient with ataxia telangiectasia patient.
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pes cavus, superficial and deep sensory impairment, hypo/
arreflexia, become apparent. The most distinctive clini-
cal signs in AOA1 are related to external eye movements: 
gaze-evoked nystagmus (found in all patients), oculomo-
tor apraxia (seen in 86%), saccadic pursuit, hypometric 
saccades, fixation instability, and excessive blinking45-47. In 
advanced stages, oculomotor apraxia might be masked by 
progressive external ophthalmoparesis, which starts with 
upward gaze paralysis45. Optic atrophy and retinal exsu-
dative lesions have been occasionally reported (Barbot, 
2001; Le Ber, 2003). Variable cognitive impairment might 
be seen and mental retardation is not uncommon46,47. 
Laboratory findings include hypoalbuminemia and 
hypercholesterolemia46,47. Elevated creatine kinase is occa-
sionally detected47. Nerve conduction velocity studies dis-
close sensory-motor axonal neuropathy. MRI reveals marked 
cerebellar atrophy, mild brainstem atrophy and, in advanced 
cases, cortical atrophy45-47. Loss of myelinated fibers with 
maintenance of amyelinic ones is seen at sural nerve45,47.
AOA1 is caused by mutation in APTX gene, which en-
codes aprataxin, a nuclear protein involved in single-
strand DNA repair, acting in the same pathway of the ATM 
protein39,46. Several mutations have been reported so far, 
most of them in exons 5, 6, and 7 of APTX gene47. This con-
dition was originally reported in Japan (where it is the most 
common cause of ARA) but is found worldwide. In Por-
tugal, AOA1 is the second most common cause of ARA46.
Ataxia with oculomotor apraxia type 2
Ataxia with oculomotor apraxia type 2 (AOA2) is char-
acterized by global progressive ataxia with onset usually 
between 8 and 25 years of age48,49, dysarthria, axonal mo-
tor sensory neuropathy, and oculomotor apraxia, which 
is seen in less than 50% of cases48-50. Saccadic pursuit is 
seen in all patients, gaze evoked nystagmus in 89%, and 
bilateral limited abduction of the eyes with strabismus in 
61% of the patients48. Dystonia, head and postural tremor, 
chorea, dysphagia, pes cavus, and scoliosis are occasional-
ly seen. Cognitive function is usually preserved, but exec-
utive dysfunction is sometimes observed48-50. Premature 
ovarian failure was also reported in some patients48. Pro-
gression is slow, and most patients are wheelchair bound 
10 years after its onset48,49. 
Serum alpha-fetoprotein is mildly to moderately el-
evated in all patients with AOA239,48-50. Increased serum 
creatine kinase, cholesterol, and immunoglobulin IgG and 
IgA, and reduced serum albumin are inconstantly seen48,50. 
Brain MRI discloses diffuse cerebellar atrophy, more in-
tense in the vermis, occasionally associated with pontine 
atrophy50. Nerve conduction studies detect sensory-mo-
tor axonal neuropathy and nerve biopsy demonstrates 
that large myelinated fibers are more severely affected 
than thin ones48,50.
AOA2 is caused by mutation in SETX gene (encod-
ing senataxin), a protein with DNA and RNA helicase ac-
tivity and which is involved in RNA processing and DNA 
repair39,49,50. Amyotrophic lateral sclerosis type 4 (ALS4), is 
caused by dominant mutations in senataxin50.
Ataxia with oculomotor apraxia type 3 
Ataxia with oculomotor apraxia type 3 (AOA3) is a re-
cently described ARA with a phenotype similar to ataxia-
telangiectasia, but with onset after 8 years of age. Report-
ed clinical features are ataxic gait, dysarthria, oculomotor 
apraxia and cerebral atrophy. No telangiectasia, biochem-
ical abnormalities, or nerve conduction impairment was 
detected. Other forms of ataxia with oculomotor aprax-
ia were excluded. Studies performed in fibroblasts dem-
onstrated a defect in repairing DNA, making these cells 
sensitive to agents that cause single strand breaks in DNA. 
Nevertheless, locus for AOA3 remains elusive51. 
Spinocerebellar ataxia with axonal neuropathy type 1 
Spinocerebellar ataxia with axonal neuropathy type 
1 (SCAN1) is a rare disorder recognized in 2002 in a large 
consanguineous family of Saudi Arabia52. Age of onset is 
around 14 years, characterized by moderate ataxia, dysar-
thria, muscular weakness, distal atrophy, pes cavus and re-
duction of vibratory and postural sense. Epilepsy may oc-
cur, but there is no cognitive decline or oculomotor ab-
normality. Nerve conduction studies disclose motor-sen-
sory axonal neuropathy and biochemical tests are non di-
agnostic, but low serum albumin and elevated cholesterol 
are occasionally seen52. Mild cerebellar and cerebral atro-
phy might be present on MRI studies. SCAN1 is caused by 
mutation in TDP1 gene, which codes for tyrosil DNA phos-
phodiesterase 1 (TDP1), a protein involved in single strand 
DNA repair39,52,53. SCAN1 is an additional example of ner-
vous system vulnerability to impaired DNA repair, as oc-
curs in AOA1, AOA2 and AT52,53.
degenerAtive AtAxiAs
Degenerative ataxias have as a common feature the 
compromise of a protein that acts as a chaperone, help-
ing protein folding. Two conditions belong to this group: 
autossomal recessive ataxia of Charlevoix-Saguenay and 
Marinesco-Sjögren syndrome. 
Autosomal recessive spastic  
ataxia of Charlevoix Saguenay 
Spastic ataxia of Charlevoix-Saguenay (SACS) was first 
reported in Charlevoix and Saguenay region of northeast 
Quebec province, Canada1,54. In this area, its incidence was 
estimated in 1/1,932 newborns, and 1 in every 22 of its in-
habitants are supposed to be carrier of the mutation re-
sponsible for SACS2,55. This condition has now been re-
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Family history Excluded AD or X-linked
JS CA, CHVR
AVED ABL
RD
FA and variants
AS ASM DSM Normal
APGM
SACS*
SCAN1
AT
AT like†
AOA 1
AOA 2
CTX*
FA
AVED
ABL
IOSCA
AT
AOA 1
AOA 2
SCAN1 CQDAMSS
RD
Measure serum cholesterol Measure CoQ 10 muscle
Increased Normal Low Normal
CTX Excluded CTX CQDA Excluded 
CQDA
Hereditary cerebellar ataxia, onset < 25 years
Brain MR images
ARA
Cerebellar atrophy
No progressive cerebellar
Present Absent
Molar tooth sign
No cerebellar atrophy
Measure total and fractions cholesterol, vit E serum
Only vit E ↓ Normal All ↓
Measure serum 
phytanic acid
Normal Increased
Molecular testing FRDA
PositiveNegativeMeasure serum albumin, 
a-fetoprotein, cholesterol 
and immnunoglobulins
Progressive ataxia
Abnormal
SA, OA and/or N
Present Absent
Normal
Nerve conduction studies
*Spastic legs. ABL: abetalipoproteinemia; ACQD: ataxia with co-
enzyme Q10 deficiency; AD: autossomal dominant; ADVE: atax-
ia with vitamin E deficiency; AOA1: Ataxia with oculomotor apraxia 
type 1; AOA2: Ataxia with oculomotor apraxia type 2; APGM: atax-
ia with mutation in polymerase gamma; ARA: autosomal recessive 
ataxia; AS: axonal sensory neuropathy; ASM: axonal sensoriomo-
tor neuropathy; AT: ataxia-telangiectasia; ATlike: ataxia telangiecta-
sia like disorder; CA: Cayman ataxia; CHVR: Cerebellar hypoplasia 
associated to VLDL receptor; CTX: cerebrotendinous xanthomato-
sis; DSM: demyelinating sensoriomotor neuropathy; FA: Friedreich 
ataxia; IOSCA: Infantile onset spinocerebellar ataxia; JS: Joubert 
syndrome; MSS: Marinesco Sjögren syndrome; N: nystagmus; OA: 
oculomotor apraxia; RD: Refsum disease; SA: saccades abnormi-
ties; SACS: Spastic ataxia of Charlevoix Saguenay; SCAN1: Spi-
nocerebellar ataxia with axonal neuropathy type 1
Fig 4. Algorithm for diagnostic of the mains autosomal recessive ataxias.
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ported worldwide, but the largest series remains from 
Canada1,54-56.
Clinically, SACS is characterized by delay in acquiring 
independent walk, frequent falls and gait instability55. Dis-
ease progression is slow and ataxic gait; dysarthria and 
spastic paraplegia are the major manifestations in the first 
two decades. Later, lower limb peripheral neuropathy can 
also be detected. As disease evolves, pyramidal signs can 
be masked by progression of peripheral neuropathy, with 
the exception of the Babinski sign, which is usually pres-
ent even in later stages of disease. Distal atrophy, pes ca-
vus, and hammer toes are commonly seen as disease ad-
vances54-56. In some patients, fundoscopy discloses hyper-
myelination of fibers radiating from optic disk and em-
bedding the retinal vessels, a very peculiar finding. Hor-
izontal nystagmus, saccadic alteration of smooth ocular 
pursuuit and miccional urgency might be present54,55. Mild 
mental retardation and cognitive decline were occasional-
ly reported54. Patients usually become wheelchair bound 
after the 3rd or 4th decades of life and life expectancy 
is reduced as they become bedridden. During pregnancy, 
disease progression is apparently accelerated in affect-
ed women55.
Nerve conduction velocity studies usually disclose an 
axonal neuropathy with mild demyelination, sensory fi-
bers are more severely affected that motor fibers. The 
most consistent neuroimaging finding is cerebellar vermis 
atrophy, mostly from its superior portion54-56. Cervical and 
thoracic spinal cord thinning are occasionally reported55. 
At an early stage, SACS can be misdiagnosed as cere-
bral palsy55. Diagnosis is based on clinical manifestations 
and confirmed by mutation analysis of SACS gene located 
on 13q1154,56. Putative role of its product, sacsin, is to help 
protein folding, acting as a chaperone56. How sacsin de-
ficiency causes neurodegeneration it is not known, but it 
has been reported to interact with Ataxin-1, the cause of 
Autosomal Dominant Spinocerebellar Ataxia type 156. 
Marinesco-Sjögren syndrome 
Marinesco-Sjögren syndrome (MSS) is a rare, multisys-
tem disorder, characterized by congenital or early-onset 
cataracts, developmental delay, cerebellar ataxia and mild 
to severe mental retardation. Microcephaly, nystagmus, 
short stature, scoliosis, hypergonadotrophic hypogonad-
ism and myopathy are common additional features57,58. Pe-
ripheral neuropathy, deafness, optic atrophy, strabismus, 
spasticity and seizures might be present57. Disease pro-
gression is slow and long survival can be expected2. 
Brain MRI usually discloses cerebellar atrophy or hy-
poplasia. Additional uncommon findings are cortical at-
rophy and leucoencephalopathy. Serum creatine kinase is 
usually elevated and muscle biopsy show chronic myopa-
thy with rimmed subsarcolemmal vacuoles57,58. 
MSS is caused by mutations in SIL1 gene (encoding a 
nucleotide exchange factor for heat-shock protein 70 fam-
ily member HSPA5). Heat-shock protein 70 family mem-
bers are the highly conserved molecular chaperones that 
assist in stabilization and folding of newly synthesized 
polypeptides. Decrease of SIL1 gene product leads to a re-
duction of protein synthesis in endoplasmic reticulum58,59. 
conclusion
Differential diagnosis of ARA is a difficult task, as there 
is a clear overlap of clinical manifestations among sever-
al previously discussed conditions. Table 3 presents the 
main characteristics of each these disorders and Fig 4 is 
a proposed algorithm to help investigation of this group 
of diseases. Nevertheless, we should be aware that ataxia 
might be a symptom in many other progressive disorders, 
affecting primarily white matter (e.g., metachromatic leu-
kodystrophy, leukoencephalopathy with vanishing white 
matter, Paelizeus-Merzbacher disease, X-linked adrenoleu-
kodystrophy), neurons (e.g. neuronal lipofuscinosis ceroid, 
juvenile Tay-Sachs disease), or leading to a more wide-
spread brain malformation or systemic manifestations, as 
it happens in pontocerebellar hypoplasia and congeni-
tal disorders of glycosilation (CDG). Non progressive cer-
ebellar symptoms are also prominent in ataxic cerebral 
palsy, an important differential diagnosis for early-onset 
ARA. It is also important to remind that all spinocerebel-
lar ataxias (SCAs) inherited as a dominant trait are out of 
the scope of this review. 
Currently, neuroimaging studies, especially brain MRI, 
are particularly important in ARA work-up and to help 
detection of cerebellar malformations and atrophy. Nor-
mal MRI is expected in some disorders, as FA and AVED. 
Nerve conduction velocity studies and, in some cases, 
electromyography are useful for evaluation of some pa-
tients, even in the absence of clinical signs of peripher-
al neuropathy or myopathy. Elevation of serum alpha-fe-
toprotein is characteristic of AT and AOA2. More specific 
biochemical tests, as determination of vitamin E and phy-
tanic acid should not be neglected, once they can help 
the diagnosis of some treatable forms of ARA. Determi-
nation of serum cholestanol and muscle CoQ10 are per-
formed in a few specialized centers around the world but 
both CTX and ataxia with CoQ deficiency are potential-
ly treatable. 
Molecular analysis access is limited, but it is feasible 
for diseases as FA and, in lesser degree, AOA1 and AOA2. 
Many patients with putative ARA remain undiagnosed, 
and is expected that new forms of ARA will be recog-
nized in the near future. The number of recessive ataxias 
is already high, and we will probably keep counting new 
arrivals for the forthcoming years. 
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